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SUSTAINED RELEASE DRUG DELIVERY 
DEVICES 
FIELD OF THE INVENTION 
The present invention relates to a novel sustained 
release drug delivery device comprising an inner core 
or reservoir containing an agent effective in obtaining a 
desired local or systemic physiological or pharmacolog 
ical effect, a ?rst coating essentially impermeable to the 
passage of the effective agent, and a second coating 
permeable to the passage of the effective agent. The 
?rst coating covers at least a portion of the inner core; 
however, at least a small portion of the inner core is not 
coated with the ?rst coating layer. The second coating 
layer essentially completely covers the ?rst coating 
layer and the uncoated portion of the inner core. The 
portion of the inner core which is not coated with the 
?rst coating layer allows passage of the agent into the 
second coating layer thus allowing controlled release. 
BACKGROUND OF THE INVENTION 
Over the years, various drugs have been developed to 
assist in the treatment of a wide variety of ailments and 
diseases. However, in many instances such drugs are 
not capable of being administered either orally or intra 
venously without the risk of various detrimental side 
effects. 
For example, intravenous ganciclovir (GCV) is effec 
tive in the treatment of CMV retinitis in AIDS patients, 
but bone marrow toxicity limits its usefulness. The inci 
dence of neutropenia (absolute neutrophil count 
< 1000) during intravenous GCV therapy ranges from 
30 to 50%. Continuous maintenance GCV therapy is 
necessary to prevent progression or recrudescence of 
the disease, but despite maintenance therapy 30 to 50% 
of patients experience a relapse during treatment. Other 
problems associated with systemic GCV administration 
include the risk of sepsis related to permanent indwell 
ing catheters and the inability to receive concurrent 
therapy with zidovudine (AZT) which has been shown 
to prolong life and improve the immune function in 
AIDS patients. 
Intravitreal GCV injections of 200 to 400 pg adminis 
tered once or twice weekly have resulted in temporary 
remission of CMV retinitis in AIDS patients. Intravit 
real GCV injections may provide a higher intraocular 
drug concentration than systemic therapy and reduce 
the incidence of neutropenia. Current treatment of 
CMV retinitis in AIDS patients is clearly suboptimal. 
Ganciclovir is virustatic and thus disease inhibition 
requires maintenance drug administration. 
Due to the risks that certain drugs impose, research 
ers have developed systems for administering such 
drugs to aid in the treatment of these ailments and dis 
eases. Many of these systems provide a release rate 
which reduces the occurrence of detrimental side ef 
fects. 
One such delivery device is an orally administered 
pill or capsule which contains a drug encapsulated 
within various layers of a composition that dissolves 
over a period of time in the digestive tract, thereby 
allowing a gradual or slow release of the drug into the 
system. 
Another type of device for controlling the adminis 
tration of such drugs is produced by coating a drug with 
a polymeric material permeable to the passage of the 










ticularly suitable for treating a patient at a speci?c local 
area without having to expose the patient’s entire body 
to the drug. This is advantageous because any possible 
side effects of the drug could be minimized. 
Such systems are particularly suitable for treating 
ailments affecting the eye. Advances for administering a 
drug to the external surface of the eye are disclosed in 
U.S. Pat. No. 4,014,335 to Arnold. Arnold describes 
various ocular inserts that act as a deposit or drug reser 
voir for slowly releasing a drug into the tear ?lm for 
prolonged periods of time. These inserts are fabricated 
of a ?exible polymeric material that is biologically inert, 
non-allergenic, and insoluble in tear ?uid. To initiate the 
therapeutic programs of these devices, the ocular inserts 
are placed in the cul-de-sac between the sclera of the 
eyeball and the eyelid for administering the drug to the 
eye. 
Devices formed of polymeric materials that are insol 
uble in tear ?uid retain their shape and integrity during 
the course of the needed therapy to serve as a drug 
reservoir for continuously administering a drug to the 
eye and the surrounding tissues at a rate that is not 
effected by dissolution or erosion of the polymeric ma 
terial. Upon termination of the desired therapeutic pro 
gram, the device is removed from the cul-de-sac. 
Another type of device used for sustained release of a 
drug to the external surface of the eye, described in U.S. 
Pat. No. 3,416,530, is manufactured with a plurality of 
capillary openings that communicate between the exte 
rior of the device and the interior chamber generally 
de?ned from a polymeric membrane. While these capil 
lary openings in this construction are effective for re 
leasing certain drugs to the eye, they add considerable 
complexity to the manufacture of the device because it 
is dif?cult to control the size of these openings in large 
scale manufacturing using various polymers. 
Another device, described in U.S. Pat. No. 3,618,604, 
does not involve such capillary openings, but instead 
provides for the release of the drug by diffusion through 
a polymeric membrane. The device, in a preferred em 
bodiment, as disclosed in that patent, comprises a sealed 
container having the drug in an interior chamber. None 
theless, as described in U.S. Pat. No. 4,014,335, certain 
problems have been identi?ed with such devices such as 
the dif?cult task of sealing the margins of the membrane 
to form the container. In addition, stresses and strains 
introduced into the membrane walls from deformation 
during manufacturing of those devices may cause the 
reservoir to rupture and leak. 
Another such device, described in U.S. Pat. No. 
4,014,335, comprises a three-layered laminant having a 
pair of separate and discrete ?rst and third walls formed 
of a material insoluble in tear ?uid with one of the walls 
formed of a drug release material permeable to the 
passage of drug and the other wall formed of a material 
impermeable to the passage of the drug. 
The above described systems and devices are in 
tended to provide sustained release of drugs effective in 
treating patients at a desired local or systemic level for 
obtaining certain physiological or pharmacological ef 
' fects. However, there are many disadvantages associ 
ated with their use including the fact that it is often 
times dif?cult to obtain the desired release rate of the 
drug. The need for a better release system is especially 
signi?cant in the treatment of CMV retinitis. Thus, 
there remains a long-felt need in the art for an improved 
system for providing sustained release of a drug to a 
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patient to obtain a desired local or systemic physiolog 
ical or pharmacological effect. In addition, all of these 
devices release their drug into the tear ?lm. If relatively 
high levels are required inside the eye, such devices are 
essentially useless. 
SUMMARY OF THE INVENTION 
It is, therefore, a primary objective of the present 
invention to provide a device suitable for the controlled 
and sustained release of a composition effective in ob 
taining a desired local or systemic physiological or 
pharmacological effect. 
The device, in one embodiment, includes an inner 
core or reservoir which contains an agent effective in 
obtaining the desired effect. The device further includes 
a ?rst coating layer. The ?rst coating layer is essentially 
impermeable to the passage of the agent and covers a 
portion of the inner core. The ?rst coating layer blocks 
passage of the agent from the inner core at those sides 
where it contacts the inner core. The remaining portion 
of the inner core which is not blocked allows a con 
trolled amount of the agent from the inner core to pass 
into the second coating layer. The second coating layer 
is permeable to the passage of the agent and covers 
essentially the entire ?rst coating layer and the exposed 
inner core. The ?rst coating layer is positioned between 
the inner core and the second coating layer in order to 
control the rate at which the agent permeates through 
the second coating layer-. 
Another object of the present invention is to provide 
a method for treating a mammalian organism, e. g., hu 
man, to obtain a desired local or systemic physiological 
or pharmacological effect. The method includes posi 
tioning the sustained released drug delivery system at an 
area wherein release of the agent is desired and allowing 
the agent to pass through the second coating to the 
desired area of treatment. 
Another object of the present invention is to provide 
an ocular device suitable for direct implantation into the 
vitreous of the eye. Such devices of the present inven 
tion are surprisingly found to provide sustained con 
trolled release of various compositions to treat the eye 
without risk of detrimental side effects. 
Another object of the present invention is to provide 
an ocular delivery system that could be applied to an 
intraocular lens to prevent inflamation or posterior 
capsular opaci?cation. 
With the foregoing as well as other objects, advan 
tages, features and aspects of the invention that will 
become hereinafter apparent, the nature of the inven 
tion may be more clearly understood by reference to the 
detailed description of the invention and to the ap 
pended claims. 
BRIEF DESCRIPTION OF THE DRAWINGS 
In the drawings, which are not drawn to scale, but are 
set forth to illustrate various embodiments of the inven 
tion, the ?gures are as follows: 
FIG. 1 is an enlarged view of one embodiment of the 
sustained release drug delivery device showing inner 
core, ?rst coating layer and second coating layer; 
FIG. 2 is an enlarged cross sectional schematic of one 
embodiment of the sustained release drug delivery de 
vice showing inner core, ?rst coating layer and second 
coating layer; 
FIG. 3 is a graph showing the concentration of ganci 
clovir found in test rabbits and delivered by an ocular 











FIG. 4 is a graph showing the concentration of ganci 
clovir found in humans and delivered by an ocular 
device of the present invention over time; 
FIG. 5 is a graph showing the concentration of 5 
fluorouracil (S-FU) delivered by devices of the present 
invention over time; and 
FIG. 6 illustrates the intraocular pressure of monkeys 
over time, wherein under the conjunctiva of one eye of 
each monkey was implanted a device of the present 
invention. 
DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENTS OF THE 
INVENTION 
More speci?cally, the present inventors have surpris 
ingly discovered a device that is suitable for the con 
trolled and sustained release of an agent effective in 
obtaining a desired local or systemic physiological or 
pharmacological effect. 
The device includes an inner core or reservoir which 
contains an agent effective in obtaining a desired effect. 
The device further includes a ?rst coating layer and a 
second coating layer. The ?rst coating layer covers 
only a portion of the inner core and is impermeable to 
the passage of the agent. The second coating layer cov 
ers all of the inner core and the ?rst coating layer and is 
permeable to the passage of the agent. The portion of 
the inner core that is not coated with the ?rst coating 
layer facilitates passage of the agent through the second 
coating layer. 
Speci?cally, the ?rst coating layer is positioned be 
tween the inner core and the second coating layer such 
that it blocks the passage of the agent through the adja 
cent portions of the second coating layer thus control 
ling the rate of passage of the agent. 
FIG. 1 illustrates one embodiment of the sustained 
release drug delivery device of the present invention. 
While the device shown in FIG. 1 is cylindrical, the 
device could be any shape. The device comprises an 
inner core or reservoir 5, an impermeable coating 10 
which is impermeable to the passage of the agent in the 
core or reservoir 5, and a permeable coating 15 which is 
permeable to the passage of the agent in the core or 
reservoir 5. FIG. 1 further shows an impermeable cap 
20 and suture tag 25. 
FIG. 2 illustrates, in cross section, the device shown 
in FIG. 1. As illustrated, there may be a permeable 
coating 30 between the core or reservoir 5 and the 
impermeable coating 10. The permeable coating 30 may 
be made of the same material as the permeable coating 
15. In the embodiment illustrated in FIG. 2, the imper 
meable cap 20 is positioned such that there is a passage 
35 which allows passage of the agent in the core or 
reservoir. The impermeable coating 20 is positioned 
between the permeable coating 15 and the reservoir or 
core 5. The suture tag 25 is attached to the permeable 
coating 15. 
The invention further relates to a method for treating 
a mammalian organism to obtain a desired local or sys 
temic physiological or pharmacological effect. The 
method includes administering the sustained release 
drug delivery system to the mammalian organism and 
allowing the agent effective in obtaining the desired 
local or systemic effect to pass through the second 
coating to contact the mammalian organism. The term 
administering, as used herein, means positioning, insert 
ing, injecting, implanting, or any other means for expos 
ing the device to a mammalian organism. The route of 
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administration depends on a variety of factors including 
type of response or treatment, type of agent and pre 
ferred site of administration. 
The devices in certain embodiments have applicabil 
ity in providing a controlled and sustained release of 
agents effective in obtaining a desired local or systemic 
physiological or pharmacological effect relating at least 
to the following areas: treatment of cancerous primary 
tumors, (e.g., glioblastoma); chronic pain; arthritis; 
rheumatic conditions; hormonal de?ciencies such as 
diabetes and dwar?sm; and modi?cation of the immune 
response such as in the prevention of transplant rejec 
tion and in cancer therapy. A wide variety of other 
disease states may also be prevented or treated using the 
drug delivery device of the present invention. Such 
disease states are known by those of ordinary skill in the 
art. For those not skilled in the art, reference may be 
made to Goodman and Gilman, The Pharmacological 
Basis of Therapeutics, 8th Ed., Pergamon Press, NY, 
1990; and Remington's Pharmaceutical Sciences, 18th 
Ed., Mack Publishing Co., Easton, Pa., 1990; both of 
which are incorporated by reference herein. 
In addition, the devices are suitable for use in treating 
mammalian organisms infected with AIDS and AIDS 
related opportunistic infections such as cytomegalovi 
rus infections, toxoplasmosis, pneumocystis carinii and 
mycobacten'um avium intercellular. 
The devices are particularly suitable for treating ocu 
lar conditions such as glaucoma, proliferative vi 
treoretinopathy, diabetic retinopathy, uveitis, and kera 
titis. The devices are also particularly suitable for use as 
an ocular device in treating mammalian organisms suf 
fering from cytomegalovirus retinitis wherein the de 
vice is surgically implanted within the vitreous of the 
eye. 
As described above, the inner core or reservoir con 
tains an agent effective in obtaining a desired local or 
systemic physiological or pharmacological effect. The 
following classes of agents could be incorporated into 
the devices of the present invention: anesthetics and 
pain killing agents such as lidocaine and related com 
pounds and benzodiazepam and related compounds; 
‘ anti-cancer agents such as S-fluorouracil, adriamycin 
and related compounds; anti-in?ammatory agents such 
as 6-mannose phosphate; anti-fungal agents such as 
?uconazole and related compounds; anti-viral agents 
such as trisodium phosphomonoformate, tri?uoro 
thymidine, acyclovir, ganciclovir, DDI and AZT; cell 
transport/mobility impending agents such as colchi 
cine, vincristine, cytochalasin B and related com 
pounds; antiglaucoma drugs such as beta-blockers: 
timolol, betaxolol atenolol, etc; immunological response 
modifiers such as muramyl dipeptide and related com 
pounds; peptides and proteins such as cyclosporin, insu 
lin, growth hormones, insulin related growth factor, 
heat shock proteins and related compounds; steroidal 
compounds such as dexamethasone, prednisolone and 
related compounds; and carbonic anhydrize inhibitors. 
In addition to the above agents, other agents are 
suitable for administration to the eye and its surround 
ing tissues to produce a local or a systemic physiologic 
or pharmacologic bene?cial effect. Examples of such 
agents include antibiotics such as tetracycline, chlortet 
racycline, bacitracin, neomycin, polymyxin, gramicidin, 
goxytetracycline, chloramphenicol, gentamycin, and 
erythromycin; antibacterial such as sulfonamides, sulfa 
cetamide, sulfamethizole and sul?soxazolc; antivirals, 











such as nitrofurazone and sodium propionate; antialler 
genics such as antazoline, methapyriline, chlorphenira 
mine, pyrilamine and prophenpyridamine; anti-in?am 
matories such as hydrocortisone, hydrocortisone ace 
tate, dexamethasone 21-phosphate, fluocinolone, med 
rysone, methylprednisolone, prednisolone 2l-phos 
phate, prednisolone acetate, ?uoromethalone, betame 
thasone and triminolone; decongestants such as phenyl 
ephrine, naphazoline, and tetrahydrazoline; miotics and 
anti-cholinesterase such as pilocarpine, eserine salicyl 
ate, carbachol, di-isopropyl ?uorophosphate, phospho 
line iodine, and demecarium bromide; mydriatics such 
as afropine sulfate, cyclopentolate, homatropine, sco 
polamine, tropicamide, eucatropine, and hydroxyam 
phetamine; and sympathomimetics such as epinephrine. 
Once again, reference may be made to any standard 
pharmaceutical textbook such as Remington’s Pharma 
ceutical Sciences for the identify of other agents. 
Any pharmaceutically acceptable form of such a 
compound may be employed in the practice of the pres 
ent invention, i.e., the free base or a pharmaceutically 
acceptable salt or ester thereof. Pharmaceutically ac 
ceptable salts, for instance, include sulfate, lactate, ace 
tate, stearate, hydrochloride, tartrate, maleate and the 
like. 
A large number of polymers can be used to construct 
the devices of the present invention. The only require 
ments are that they are inert, non-immunogenic and of 
the desired permeability. 
Materials that may be suitable for fabricating the ?rst 
or second coating layer of the device include naturally 
occurring or synthetic materials that are biologically 
compatible with body ?uids and eye tissues, and essen 
tially insoluble in body ?uids with which the material 
will come in contact. The use of rapidly dissolving 
materials or materials highly soluble in eye ?uids are to 
be avoided since dissolution of the wall would affect the 
constancy of the drug release, as well as the capability 
of the system to remain in place for a prolonged period 
of time. 
Naturally occurring or synthetic materials that are 
biologically compatible with body ?uids and eye tissues 
and essentially insoluble in body ?uids which the mate 
rial will come in contact include, but are not limited to, 
polyvinyl acetate, cross-linked polyvinyl alcohol, cross 
linked polyvinyl butyrate, ethylene ethylacrylate co 
polymer, polyethyl hexylacrylate, polyvinyl chloride, 
polyvinyl acetals, plasiticized ethylene vinylacetate 
copolymer, polyvinyl alcohol, polyvinyl acetate, ethyl 
ene vinylchloride copolymer, polyvinyl esters, polyvi 
nylbutyrate, polyvinylformal, polyamides, polymethyl 
methacrylate, polybutylmethacrylate, plasticized poly 
vinyl chloride, plasticized nylon, plasticized soft nylon, 
plasticized polyethylene terephthalate, natural rubber, 
polyisoprene, polyisobutylene, polybutadiene, polyeth 
ylene, polytetrafluoroethylene, polyvinylidene chlo 
ride, polyacrylonitrile, cross-linked polyvinylpyrroli 
done, polytri?uorochloroethylene, chlorinated poly 
ethylene, poly(l,4°-isopropylidene diphenylene carbon 
ate), vinylidene chloride, acrylonitrile copolymer, vinyl 
chloride-diethyl fumerale copolymer, silicone rubbers, 
especially the medical grade polydimethylsiloxanes, 
ethylene-propylene rubber, silicone-carbonate copoly 
mers, vinylidene chloride-vinyl chloride copolymer, 
vinyl chloride-acrylonitrile copolymer and vinylidene 
chloride-acrylonitride copolymer. 
Speci?cally, the ?rst layer of the device of the pres 
ent invention may be made of any of the above-listed 
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polymers or any other polymer which is biologically 
compatible with body ?uids and eye tissues, essentially 
insoluble in body ?uids which the material will come in 
contact and essentially impermeable to the passage of 
the effective agent. The term impermeable, as used 
herein, means that the layer will not allow passage of 
the effective agent at a rate required to obtain the de 
sired local or systemic physiological or pharmacologi 
cal effect. 
The ?rst layer must be selected to be impermeable, as 
described above, to the passage of the agent from the 
inner core out to adjacent portions of the second coat 
ing layer. The purpose is to block the passage of the 
agent to those portions and thus control the release of 
the agent out of the drug delivery device. 
The composition of the ?rst layer, e. g., the polymer, 
must be selected so as to allow the above-described 
controlled release. The preferred composition of the 
?rst layer will vary depending on such factors as the 
active agent, the desired rate of control and the mode of 
administration. The identity of the active agent is im 
portant since the size of the molecule, for instance, is 
critical in determining the rate of release of the agent 
into the second layer. 
Since the ?rst coating layer is essentially imperme 
able to the passage of the effective agent, only a portion 
of the inner core or reservoir may be coated with the 
?rst coating layer. Depending on the desired delivery 
rate of the device the ?rst coating layer may coat only 
a small portion of the surface area of the inner core for 
faster release rates of the effective agent or may coat 
large portions of the surface area of the inner core for 
slower release rates of the effective agent. 
For faster release rates, the ?rst coating layer may 
coat up to 10% of the surface area of the inner core. 
Preferably, approximately 5-10% of the surface area of 
the inner core is coated with the ?rst coating layer for 
faster release rates. 
For slower release rates, the ?rst coating layer may 
coat at least 10% of the surface area of the inner core. 
Preferably, at least 25% of the surface area of the inner 
core is coated with the ?rst coating layer. For even 
slower release rates, at least 50% of the surface area 
may be coated. For. even slower release rates, at least 
75% of the surface area may be coated. For even slower 
release rates, at least 95% of the surface area may be 
coated. 
Thus, any portion of the surface area of the inner core 
up to but not including 100% may be coated with the 
?rst coating layer as long as the desired rate of release 
of the agent is obtained. 
The ?rst coating may be positioned anywhere on the 
inner core, including but not limited to the top, bottom 
or any side of the inner core. In addition, it could be on 
the top and a side, or the bottom and a side, or the top 
and the bottom, or on opposite sides or on any combina 
tion of the top, bottom or sides. 
The second layer of the device of the present inven 
tion must be biologically compatible with body ?uids 
and eye tissues, essentially insoluble in body ?uids 
which the material will come in contact and permeable 
to the passage of the agent or composition effective in 
obtaining the desired effect. 
The effective agent diffuses in the direction of lower 
chemical potential, i.e., toward the exterior surface of 
the device. At the exterior surface of the device, equilib 
rium is again established. When the conditions on both 








stant, a steady state ?ux of the effective agent will be 
established in accordance with Fick’s Law of Diffusion. 
The rate of passage of the drug through the material by 
diffusion is generally dependent on the solubility of the 
drug therein, as well as on the thickness of the wall. 
This means that selection of appropriate materials for 
fabricating the wall will be dependent on the particular 
drug to be used. 
The rate of diffusion of the effective agent through a 
polymeric layer of the present invention may be deter 
mined via diffusion cell studies carried out under sink 
conditions. In diffusion cell studies carried out under 
sink conditions, the concentration of drug in the recep 
tor compartment is essentially zero when compared to 
the high concentration in the donor compartment. 
Under these conditions, the rate of drug release is given 
by: 
where Q is the amount of drug released, t is time, D is 
the diffusion coef?cient, K is the partition coef?cient, A 
is the surface area, DC is the difference in concentration 
of the drug across the membrane, and h is the thickness 
of the membrane. 
In the case where the agent diffuses through the layer 
via water ?lled pores, there is no partitioning phenom 
ena. Thus, K can be eliminated from the equation. 
Under sink conditions, if release from the donor side is 
very slow, the value DC is essentially constant and 
equal to the concentration of the donor compartment. 
Release rate therefore becomes dependent on the sur 
face area (A), thickness (h) and diffusivity (D) of the 
membrane. In the construction of the device of the 
present invention, the size (and therefore, surface area) 
is mainly dependent on the size of the effective agent. 
Thus, permeability values may be obtained from the 
slopes of a Q versus time plot. The permeability P, can 
be related to the diffusion coef?cient D, by: 
Once the permeability is established for the coating 
permeable to the passage of the agent, the surface area 
of the agent that must be coated with the coating imper 
meable to the passage of the agent may be determined. 
This is done by progressively reducing the available 
surface area until the desired release rate is obtained. 
Exemplary microporous materials suitable for use as 
a second coating layer, for instance, are described in 
U.S. Pat. No. 4,014,335 which is incorporated herein by 
reference in its entirety. These materials include cross 
linked polyvinyl alcohol, polyolefms or polyvinyl chlo 
rides or cross-linked gelatins; regenerated, insoluble, 
nonerodible cellulose, acylated cellulose, esteri?ed cel 
luloses, cellulose acetate propionate, cellulose acetate 
butyrate, cellulose acetate phthalate, cellulose acetate 
diethyl-aminoacetate; polyurethanes, polycarbonates, 
and microporous polymers formed by co-precipitation 
of a polycation and a polyanion modi?ed insoluble col 
lagen. Cross-linked polyvinyl alcohol is preferred. The 
second coating layer is selected so as to slow release of 
the agent from the inner core into contact with a mam 
malian organism, e.g., a human. The second coating 
layer need not provide gradual release or control of the 
agent into the biological environment, however, the 
second coating layer may be advantageously selected to 
also have that property or feature. 
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The devices of the present invention may be made in 
a wide variety of ways, such as by obtaining an effective 
amount of the agent and compressing the agent to a 
desired shape. Once shaped, a first coating layer may be 
applied. In the case of the ethylene vinyl acetate, the 
?rst coating layer may be applied directly in the form of 
a sheet or membrane to the outer surface of the agent. 
Optionally, the effective agent may have a permeable 
coating applied to its entire surface prior to coating 
with the ?rst coating layer. See FIG. 2. Once the ?rst 
coating layer is applied to the device, the second coat 
ing layer may be applied. In the case of polyvinyl alco 
hol, the second coating may be applied by dipping the 
device one or more times in a solution containing the 
desired polymer. Optionally, the second coating layer 
may be applied by dropping, spraying, brushing or 
other means of coating the outer surface of the device 
with the polymer solution. When using a polyvinyl 
alcohol solution to obtain the second coating layer, the 
desired thickness may be obtained by applying several 
coats. Each coat may be dried prior to applying the next 
coat. Finally, the device may be heated to adjust the 
permeability of the outer coating. 
The above description of how to make the devices of 
the present invention is merely illustrative and should 
not be considered as limiting the scope of the invention 
in any way, as various compositions are well known by 
those skilled in the art. In particular, the methods of 
making the device depends on the identity of the active 
agent and polymers selected. Given the active agent, 
and the composition of both the ?rst coating and the 
second coating, one skilled in the art could easily make 
the devices of the present invention using conventional 
coating techniques. 
The method for treating a mammalian organism to 
obtain a desired local or systemic physiological or phar 
macological effect includes administering the sustained 
release drug delivery device of the present invention to 
the mammalian organism and allowing the agent to pass 
through the device to come in direct contact with the 
mammalian organism. 
The drug delivery system of the present invention 
may be administered to a mammalian organism via any 
route of administration known in the art. Such routes of 
administration include intraocular, oral, subcutaneous, 
intramuscular, intraperitoneal, intranasal, dermal, and 
the like. In addition, one or more of the devices may be 
administered at one time or more than one agent may be 
included in the inner core. 
The drug delivery system of the present invention is 
particularly suitable for direct implantation into the 
vitreous of the eye and for application to an intraocular 
lens. 
These methods of administration and technique for 
their preparation are well known by those of ordinary 
skill in the art. Techniques for their preparation are set 
forth in Remingtan’s Pharmaceutical Sciences. 
The drug delivery system may be administered for a 
sufficient period of time and under conditions to allow 
treatment of the disease state of concern. I 
For localized drug delivery, the devices may be sur 
gically implanted at or near the site of action. This is the 
case for devices of the present invention used in treating 
ocular conditions, primary tumors, rheumatic and ar 
thritic conditions, and chronic pain. 
For systemic relief, the devices may be implanted 
subcutaneously, intramuscularly or intraperitoneally. 











systemic levels and avoid premature metabolism. In 
addition, such devices may be administered orally. 
In one embodiment of the invention, an ocular device 
containing ganciclovir as the effective agent in an effec 
tive amount to prevent a virus from replicating may be 
prepared. As further shown in the Examples which 
follow, such devices may be used to effectively combat 
and inhibit reproduction of cytomegalovirus retinitis, 
when surgically implanted into the vitreous of the eye. 
Such devices may remain in the vitreous permanently 
after treatment is complete. The preferred amount of 
ganciclovir used in these devices ranges from about 0.01 
mg to about 20 mg. More preferably, such devices con 
tain from @out 2 mg to about 10 mg of ganciclovir. 
These preferred ranges may provide sustained release of 
the ganciclovir for a period of from several hours to 
over one year. The preferred ?rst coating layer is ethyl 
ene vinyl acetate. The preferred second coating layer is 
polyvinylalcohol. When such devices are prepared for 
implantation within the vitreous of the eye, it is pre 
ferred that the device does not exceed about 5 millime 
ters in any direction. Thus, the cylindrical device 
shown in FIG. 2 would preferably not exceed 5 millime 
ters in height or diameter. In addition, the preferred 
thickness'of the ?rst coating layer ranges from about 0.1 
to about 1.0 millimeters. The preferred thickness of the 
second coating layer ranges from about 0.1 to about 2.0 
millimeters. 
In another embodiment of the invention, an ocular 
device containing S-FU as the effective agent may be 
prepared. As further shown in the Examples which 
follow, such devices may be used to effectively main 
tain the'intraocular pressure of glaucoma patients after 
?lter surgery when implanted under the conjunctiva of 
the eye. The preferred amount of ganciclovir used in 
these devices ranges from about 0.01 mg to about 20 
mg. More preferably, such devices contain from about 2 
mg to about 15 mg. These preferred ranges may provide 
sustained release of the S-FU for a period of from sev 
eral hours to over 2 months. Preferred materials include 
ethylene vinyl acetate as the ?rst coating layer and 
polyvinyl alcohol as the second coating layer. The pre 
ferred thickness of the ?rst coating layer ranges from 
about 0.01 to about 1.0 millimeters. The preferred thick 
ness of the second coating layer ranges from about 0.01 
to about 2.0 millimeters. 
Optionally, one or more of the devices could be at 
tached to an intraocular lens or the haptic extending 
therefrom. Intraocular lenses having the devices of the 
present invention attached thereto and containing 
5-FU, colchicine or dexamethasone are particularly 
suitable for treating patients that have undergone extra 
capsular cataract surgery. Speci?cally, such devices 
may be used to reduce proliferation of remnant lens 
cells thus preventing or reducing posterior capsular 
opaci?cation. 
While the above described embodiments of the inven 
tion are described in terms of preferred ranges of the 
amount of effective agent, and preferred thicknesses of 
the preferred ?rst and second coating, these preferences 
are by no means meant to limit the invention. As would 
be readily understood by one skilled in the art, the pre 
ferred amounts, materials and dimensions depend on the 
method of administration, the effective agent used, the 
polymers used, the desired release rate and the like. 
Likewise, actual release rates and release duration de 
pend on a variety of factors in addition to the above 
such as the disease state being treated, the age and con 
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dition of the patient, the route of administration as well 
as other factors which would be readily apparent to 
those skilled in the art. 
The following examples are merely illustrative of the 
present invention and they should not be considered as 
limiting the scope of the invention in any way, as these 
examples and other equivalents thereof will become 
more apparent to those skilled in the art in light of the 
present disclosure. 
EXAMPLE 1 
Intraocular Sustained Release of Antiviral Agents 
This example demonstrates that the severe problems 
associated with present GCV therapy may be avoidable 
by delivering the drug locally thus avoiding high sys 
temic drug levels. The present inventors have devel 
oped an implantable device that will release GCV 
within the eye for over 90 days. The device is composed 
of 6 mg GCV encased in layers of ethylene vinyl acetate 
(EVA) and polyvinyl alcohol (PVA). 
Characteristics of Polymers 
EVA membranes were prepared by compressing 
EVA at 180° C. under 5 tons of pressure. PVC mem 
branes were prepared from solutions of PVA which 
were dried to a ?lm and then heated to 125, 150 or 180° 
C. The permeability of EVA and PVA membranes to 
GCV was measured in vitro using parallel glass diffu 
sion chambers (Crown Glass Co., Somerville, NJ). 
One ml solutions of GCV were prepared in normal 
phosphate buffer (pH 7.4) and applied to the donor side 
of the chambers. The permeation of GCV across the 
membranes to the receptor compartment was measured 
for 3 hours at 37° C. The devices were found to release 
GCV in a linear manner for approximately 120 days in 
vitro with a mean release rate of approximately 50 
lbs/day 
Preparation and Testing of the Devices 
6 mg pellets of GCV were prepared by direct com 
pression using a 2.5 mm die. These were surrounded on 
three sides with the impermeable EVA membrane and 
then coated in a 10% PVA solution. After being al 
lowed to dry for 24 hours, the device was cured at 180° 
C. for 4.7 hours to further reduce the release rate. The 
release rate of GCV from the devices prepared above 
was measured in vitro by immersing each device in 5 ml 
of isotonic phosphate buffer (pH 7.4). One ml samples 
were periodically withdrawn and replaced with fresh 
buffer and the buffer solution was changed every 10 
days to avoid microbial growth. 
The apparent permeability coefficient of GCV across 
PVA membranes was dependent on the temperature 
which they had been treated. The change in physical 
properties of the membranes is due to alterations in 
crystal structure of polymer. The permeability of GCV 
across EVA membranes was too low for permeability 
coefficients to be calculated. The permeability of GCV 
across PVA membranes is set forth in Table l‘below. 
TABLE 1 
PERMEABILITY OF GCV ACROSS PVA MEMBRANE 
TREATED AT VARIOUS TEMPERATURES 
Membrane Papp (cm/s X l0-7) 
Treatment ('‘C.) +/-— SD, N = 4 
125 8-3 +/— 0.6 
150 2.1 +/— 0.2 












In Vivo Testing of Devices 
Devices were surgically implanted into both the sub 
conjunctival space and the vitreous of albino rabbits. 
After 10 days, the animals were sacri?ced and a histo 
logical examination was performed. In another group of 
animals, devices were implanted into the posterior 
chamber of the eye and samples of vitreous humour was 
periodically removed. In a third group of animals de 
vices were implanted into the vitreous of both eyes. The 
animals were killed 10, 30, 40, 70 and 80 days after 
implantation of the devices. The devices and vitreous 
samples removed for analysis. The concentration of 
GCV in these samples was determined by HPLC with 
UV detection at 254 nm. A C-l8 reverse phase column 
was used with mobile phase of 0.02% ammonium ace 
tate buffer (pH 4.0) and a ?ow rate of 1 ml/min. The 
effect of implantation on retinal function was assessed 
by performing electroretinogram (ERG) examinations 
before and after the study. 
Histologic examination gave no indication of toxicity 
or inflammatory reaction due to the implantation of the 
device. Some in?ammation was noted around the suture 
used to hold the device in place suggesting that this 
produced a worse reaction than the device itself. Analy 
sis of vitreal samples showed that the device maintained 
GCV levels in the vitreous at or above 2 rig/ml for over 
80 days. The ERG data suggests that the levels of GCV 
obtained cause no retinal toxicity in the rabbit eye. The 
possibility exists for drug resistance to develop in CMV 
although there have been no reports of this as yet. Resis 
tance to GCV, should it occur, could be countered by 
the use of other drugs (Foscarnet or tri?uorothymidine) 
in similar release devices. 
CONCLUSION 
The implantation of controlled release devices for the 
release of GCV appears to offer some signi?cant advan 
tages over existing therapy. The work performed in 
rabbits indicates that vitreal concentrations of GCV can 
be maintained above the ID 100 for CMV for a pro 
longed period without high systemic exposure. This 
will, if effective, treat potentially blinding CMV retini 
tis and allow concurrent therapy of AZT for HIV. It is 
anticipated that fewer complications will arise from this 
procedure than occur in repeated intravitreal injections. 
EXAMPLE 2 
Intravitreal Sustained Release of Ganciclovir: 
Membrane Permeability and Device Construction 
The following paragraphs illustrate the membrane 
permeability and device construction of particular em 
bodiments of the present invention. 
Ganciclovir was obtained from Syntex Laboratories 
as a free acid in powdered form. Alternatively, the free 
acid of ganciclovir was prepared by neutralizing an 
aqueous solution of the commercially available salt (pH 
11.2). The precipitated product was then puri?ed with 
two successive recrystallizations from 95% ethanol. 
The buffer solution was composed of sodium bicarbon 
ate (0.68%), potassium bicarbonate (0.03%), and so 
dium chloride (0.65%), in distilled water. The pH of the 
buffer solution was adjusted to 7.4 prior to use. Polyvi 
nyl alcohol (PVA) of 76—78,000 M.W. and 98% hydra 
tion was obtained from Aldrich Chemical Co. Ethylene 
vinyl acetate was obtained from Du Pont of Wilming 
ton (trade name ELVAX, grade 40w). 
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Diffusion Cell Studies 
PVA membranes were prepared by dissolving 4 
grams of PVA in 200 ml of distilled water at 60° C. The 
PVA solution was allowed to cool to 22° C. and the 
entire mixture was poured so that it completely covered 
a silicanized glass slab measuring 35 cm by 46 cm. After 
drying for 16 hours, the PVA ?lm was removed from 
the slab. Membranes prepared in this fashion were then 
heat cured in a convection oven for 4 hours at 190° C. 
Diffusion cell studies were performed by placing the 
membranes between the compartments of a glass diffu 
sion cell (Crown Glass Co., Somerville, NJ). The in 
ternal diameter of these cells was 1 cm (total surface 
area of diffusion 0.78 01112); the volume of each compart 
ment was 3 ml. Small magnetic stirring rods were 
placed in each compartment and operated by a mag 
netic stirring unit. The entire assembly was maintained 
at 37° C by a circulating water bath. Membranes were 
?rst soaked in isotonic buffered saline (pH 7.4) for 30 
minutes and then loaded into the chambers. With the 
membrane in place, buffer solution was added to each 
compartment and left in place for 30 minutes to allow 
for hydration of the membrane and then removed. A 
0.025% solution of GCV in isotonic buffered saline was 
added to the donor compartment and the buffer solution 
was added to the receptor compartment. The contents 
of the receptor compartment were periodically re 
moved for analysis and replaced with fresh buffer solu 
tion thus maintaining sink conditions. 
An ultraviolet spectrophotometry assay was used to 
determine concentrations of ganciclovir (252 nm, detec 
tion limit 0.1 pig/cc). A linear relationship between 
absorbance and concentration was demonstrated using 
known concentrations of drug in a tear buffer solution. 
Sheets of EVA membrane were prepared by com 
pressing 3.5 gm pellets under 4 metric tons at 190° C to 
a thickness of 0.6 mm. Diffusion cell studies were per 
formed with EVA membranes as described above for 
PVA. It was found that GCV did not permeate through 
the EVA layer. 
Device Construction 
Because EVA was found to be impermeable to ganci 
clovir it was used in these devices as a blocking agent. 
EVA membranes were prepared as described above. A 
six milligram pellet of GCV was compressed under 500 
pounds of pressure into pellets measuring 2.5 mm in 
diameter. 
A first type of sustained release GCV device releas 
ing 2 ug/hr was prepared by coating the 6 mg pellet of 
ganciclovir in 300 p1 of a 10% PVA solution and allow 
ing the coated pellet to dry. The pellet was then coated 
on three sides with a ?lm of prepressed EVA and 
capped by a 3 mm disc of EVA coated in 10% PVA. 
The pellet was thus completely surrounded by EVA 
apart from a thin ring of PVA between the EVA walls 
and the cap. See FIG. 2. The assembly was then com 
pletely coated in 10% PVA and allowed to dry over 
night. The embedded pellet was cut out in a disc shape 
using a 4 mm punch. A suturing strut was attached to 
the device by bonding a strip of dry 10% PVA to the 
bottom of the device with a drop of 2% PVA. The 
device was subsequently baked at 190° C for 4.75 hours. 
A second type of device releasing 5 ug/hr was pre 
pared in the same manner except that GCV pellets had 







Release Rate Studies 
The devices were placed in 10 m1 of isotonic buffered 
saline at 37° C. This solution was periodically sampled 
and changed to maintain sink conditions. The concen 
tration of GCV in these samples was determined by 
HPLC with UV detection at 254 nm absorbance. Ab 
sorbance values of the samples were converted to drug 
concentrations and cumulative drug release (average of 
three trials) was plotted against time. 
As stated above, the GCV devices released ganci 
clovir at a rate of 2:0.5 tug/hr (?rst type) and 5:1 
ug/hr (second type). 
Device/Drug Stability 
Near IR of the individual components (EVA, PVA 
and ganciclovir) showed no change after heat treat 
ment; however, the device showed a single new peak at 
approximately 2075 nm. In addition, there was no ap 
parent drug loss or decomposition after heat treatment 
of the ganciclovir pellet based on HPLC analysis, and a 
scanning EM of the device demonstrated that there 
were no holes or cracks in the walls of the device after 
heat treatment. 
EXAMPLE 3 
Intravitreal Sustained Release of Ganciclovir: In Vivo 
Pharmacokinetics and Tolerability 
The membrane permeability studies, the construction 
of the implants and the in vitro release rate studies of the 
implants used in this study are described in Example 2. 
Implants releasing 2 or 5 pg/hr in vitro were prepared. 
Implants were sterilized with ethylene oxide gas by the 
Sterile Products Division of the Veterans Administra 
tion Hospital in Lexington, Ky. Quality control was 
ensured by measuring the in vitro release rate of every 
?fth device. Sterility -was ensured by sending every 
?fth device for culture. 
New Zealand albino rabbits weighing 1.5 to 2 kg 
were used in this study. Anesthesia was provided with 
intramuscular ketamine HCl (40 mg/kg), attopine sul 
fate (0.1 mg/kg), xylazine HCl (10 mg/kg) and topical 
proparacaine (0.5%). Pupillary dilation was achieved 
with topical phenylephrine (2.5%) and tropicamide 
(1%) drops. 
A baseline photopic electroretinogram (ERG) was 
recorded preoperatively in each rabbit using a corneal 
contact lens. A Gansfeld stimulus was used to improve 
standardization of results. After sedation, the rabbits 
were placed inside a Gansfeld stimulator 20 cm away 
from the ?ash unit. Flash (cone and rod response) and 
?icker (cone response) ERGs were done under light 
adapted conditions. Graphic measurements were re 
corded, and the waveform amplitudes and implicit 
times were calculated. 
Cryopexy was then applied to the superior 180 de 
grees of the peripheral retina in each eye to decrease the 
chance of retinal detachment related to EVA/PVA 
membrane insertion or vitreous sampling. This was 
done because the pars plana of the New Zealand albino 
rabbit is poorly developed and it was therefore neces 
sary to implant the devices and take vitreous samples 
through retina. The ERG was repeated four weeks later 
immediately prior to insertion of the device. 
All intraocular procedures were done under sterile 
conditions and conformed to the ARVO speci?cations 
for the ethical treatment of experimental animals. After 
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placement of a lid speculum, a 360 degree conjunctival 
peritomy was performed. The rectus muscles were se 
cured with 2-0 black silk suture. Using indirect ophthal 
moscopy, the area of previous cryopexy was localized 
and marked with scleral diathermy. 
The EVA/PVA device was immersed in sterile saline 
prior to placement of a 7-0 silk suture through the exter 
nal PVA supporting tag. A MVR blade was used to 
create a 5 mm sclerotomy site through the area 
cryopexy. Penetration into the vitreous was veri?ed by 
direct visualization of the MVR blade through the di 
lated pupil. The device was placed into the vitreous 
cavity and secured to the sclera with the 7-0 silk suture 
that was attached to the external PVA supporting tag. 
Remaining defects in the sclera were closed with 7-0 
silk in an interrupted fashion. Topical antibiotic drops 
consisting of polymyxin B, bacitracin, and neomycin 
were instilled into each eye twice daily for three days 
after each procedure. 
In a ?rst group of nine rabbits, the right eye was 
treated with a device without GCV (control eyes), 
while the left eye was given a device containing 6 mg of 
GCV releasing at 5:1 ug/hr (treatment eyes). Vitreous 
samples were periodically removed using a 20 gauge 
needle on a tuberculin syringe. Entrance into the vitre 
ous cavity was veri?ed by observation of the needle 
through the dilated pupil. Retinal examination with 
indirect ophthalmoscope was performed on each eye 
prior to each vitreous sampling. After removal, vitreous 
samples were stored at -60° C until analyzed by 
HPLC. ERG’s were repeated one and two months after 
device implantation. 
After the last ERG, the rabbits were sacri?ced with 
an overdose of intravenous sodium pentobarbital. At 
this time, no GCV was detectable in the vitreous. Enu 
cleated eyes were ?xed in 70% formaldehyde 
glutaraldehyde solution, dehydrated in alcohol, embed 
ded in paraf?n, and sectioned with microtome. Tissues 
were stained with hematoxylin-eosin and examined 
under a light microscope. 
In a second group of 10 rabbits, a device containing 6 
mg of GCV releasing at 2i0.5 ug/hr was implanted 
into both eyes. Vitreous samples were not collected 
from the treated eyes. Instead, the rabbits were sacri 
?ced 10, 30, 40, 70 and 80 days after implantation. As 
with the ?rst group, retinal examination was performed 
with an indirect ophthalmoscope and ERGs were per 
formed immediately prior to sacri?ce. In this group, 
devices were removed from the eyes and the amount of 
GCV still present determined by HPLC. 
The animals were killed with an overdose of intrave 
nous sodium pentobarbital when no detectable GCV 
was present in the treatment eyes. Enucleated eyes were 
?xed in 20% formaldehyde-glutaraldehyde solution, 
dehydrated in alcohol, embedded in paraf?n, and sec 
tioned with a microtome. Tissues were stained with 
hematoxylin-eosin and examined by light microscopy. 
In the ?nal experimentation group, 6 mg of GCV was 
placed into the vitreous of one rabbit (both eyes) 
through the pars plana to assess retinal toxicity in the 
“worst case scenario” event of immediate device break 
down. ERGs were done preoperatively and on postop 
erative days 2, l1, and 48. 
Results 
In this investigation, mean GCV vitreous concentra 
tions in the ?rst group ranged from 14 ug/ml to 19 










tion. The calculated mean in vivo release rate was ap 
proximately 5 ug/hr. No detectable drug was measured 
72 days after device implantation in any eye from the 
?rst group. In the second group, GCV was present in 
the vitreous at over 2 ug/ml for over 80 days. Im 
planted devices were found to have released GCV at 
approximately 2 ug/hr in vivo. This would suggest that 
levels would be maintained in the vitreous for approxi 
mately 120 days. 
The device was well tolerated in both groups demon 
strating no evidence of intraocular in?ammation by 
indirect ophthalmoscopy. Five treatment eyes from the 
?rst group developed lens opaci?cation (5/9, 56%). 
None of the eyes from the control group or eyes from 
the second group developed lens opaci?cation (0/19, 
0%). Two of the 5 eyes that developed lens opaci?ca 
tion developed a dim use white cataract after direct 
trauma to the lens during vitreous sampling. The other 
eyes that developed lens opaci?cation developed a fo 
cal, nonprogressive lens opacity also believed to be 
related to vitreous sampling. No cataract formation 
occurred in any of the eyes in which a device containing 
ganciclovir was placed and no vitreous sampling was 
performed. 
Retinal detachment occurred in two treatment eyes 
(2/ 9, 22%) from group one and in none of the eyes from 
the control group or the eyes from the second group 
(O/l9, 0%). Both retinal detachments were thought to 
be related to traumatic vitreous sampling and not a 
secondary response to the device. 
No detachments or other abnormalities occurred in 
the second group of animals which were not periodi 
cally sampled. 
Flash (rod and cone response) and ?icker (cone re 
sponse) ERG measurements were obtained preopera 
tively and postoperatively in all eyes. No signi?cant 
deterioration of the ?ash or ?icker ERG wave ampli 
tudes occurred in either group one or two eyes. No 
signi?cant prolongation of the ERG implicit times oc 
curred in either group. Modest abnormalities seen in the 
postoperative ERG b-wave amplitudes and implicit 
times were most likely related to the cryopexy. 
Histological examination of the retina showed no 
signi?cant difference between the control and treatment 
eyes. Light microscopic examination of both groups 
revealed normal retinal architecture. 
The two eyes from the ?nal group that received a 6 
mg bolus dose of intravitreal GCV showed no evidence 
of toxicity by indirect ophthalmoscopy. Postopera 
tively, the photopic ?ash ERG remained unchanged 
throughout, while the photopic ?icker ERG showed a 
50% deterioration in b-wave amplitude and modest 
delay in implicit time beginning 48 hours after GCV 
administration. The ?icker ERG completely recovered 
in one eye and partially in the other 48 days after GCV 
administration. 
No observable retinal toxicity was present by ERG 
or light microscopic examination of retinal tissue post 
operatively. Chronic low concentrations of GCV ap 
pear to be well tolerated by the retina. Although some 
ERG changes were noted with the implantation of 6 mg 
of uncoated GCV it does not appear that complete 
device breakdown would result in permanent retinal 
damage. We believe that the cataracts which formed in 
the 5 eyes of group one were secondary to lens trauma 
from the repeated vitreous taps rather than drug toxic 
ity. No lens opaci?cation occurred in either the eyes 
from the control group or the eyes from the second 
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group in which frequent vitreous taps were not per 
formed. 
The device was easily inserted through the area of 
cryopexy in the rabbit. Applicants believe that the reti 
nal detachments seen in two treatment eyes of the ?rst 
group were a re?ection of the dif?culty working with 
rabbit eyes (poorly formed pars plana, low scleral rigid 
ity, and large lens) rather than complications due to the 
drug or device itself. No detachments occurred in the 
eyes from the control group or the eyes from the second 
group that were not undergoing frequent vitreous taps. 
There was minimal in?ammatory response to the 
EVA/PVA device alone. These polymers are biologi 
cally inert and are well tolerated by the eye. This is a 
non-biodegradable system. Although this may be con 
sidered a drawback, the reliable release rates over ex 
tended periods of time and the lack of in?ammatory 
response would be very dif?cult to obtain using an 
erodible drug delivery system. Our in vitro release rates 
seem to be predictive of the in vivo release rate. In the 
eyes from the second group, drug devices were con 
structed to release GCV at a slower rate to extend the 
duration of treatment. Increasing the amount of drug 
carried in the device would also be technically simple 
and could extend the duration of GCV release to the 
vitreous for several months. 
EXAMPLE 4 
Intravitreal Sustained Release of Ganciclovir In Vivo 
Pharmacokinetics and Tolerability: Human Studies 
The membrane permeability studies, the construction 
of the implants and the in vitro release rates studies of 
the implants used in this study are described in Example 
2. The devices used were those which released GCV at 
2 pg/hr. 
Eight humans infected with AIDS were used in this 
study. One eye of each patient treated with an implant 
containing ganciclovir. The implant was surgically po 
sitioned within the vitreous. The other eye of each 
patient was used as a control, that is, was not treated 
with ganciclovir. In all eight patients, vision stabilized 
in the eye treated with the implant. See Table 2 below. 
In Table 2, the ?rst column indicates the initials of the 
patient. The second column indicates the visual acuity 
of the patient prior to implantation. The third column 
indicates the visual acuity of the patient on the last day, 
the vision of the patient was checked before death. 
TABLE 2 
Vision of Patients Treated With 
Implant 
PATIENT BEFORE AFTER DAYS 
SFR 20/70 20/70 21 
ELM 20/20 20/25 28 
KRSl ci=2 cF2 24 
RM 20/80 zo/so 19 
BR 20/20 20/40 26 
CMP 20/30 20/30 9 
CRW 20/40 20/40 7 
EL 20/20 20/40 50 
lRetina was detached at time of implantation but was repaired during implantation. 
Subsequently, the retina redetached. 
2Count Fingers Vision Failure 
In addition, progression of the disease arrested or 
reversed in the eye treated with ganciclovir. Table 3 
below and the photography in FIG. 5 show the progres~ 
sion of the disease. FIG. 4 shows the concentration of 










Progression of CMV in Patients 
Treated with Implant 
PATIENT TREATED EYE CONTROL EYE 
SFR stable progressed 
ELM improved progressed 
KRS " progressed progressed 
RM improved no disease 
BR improved no disease 
CMP stable progressed 
CRW improved no d'sease 
EL improved progressed 
Visual activity was determined by a standard eye 
exam and disease progression by fundus photograph. 
Samples of vitreous from human eyes were analyzed 
by high performance liquid chromatography (HPLC) 
using a C-l8 reverse phase column with a 0.02% ammo 
nium acetate mobile phase (pH 4.0). Under these condi 
tions, GCV has a retention time of 31 minutes. This 
work has shown that implantation of the devices main 
tains GCV levels of approximately 1.5 ug/ml in the 
vitreous for over 70 days. 
EXAMPLE 5 
Sustained Release of S-FU Using a Heat Treated 
Membrane System of Layered Ethylene Vinyl Acetate 
and Polyvinyl Alcohol 
In Vitro Studies 
subconjunctival administration of 5-FU as an adjunct 
to ?ltration surgery in high risk glaucoma patients is 
attended by the necessity of multiple subconjunctival 
injections and the potentially serious complications due 
to delayed wound healing. Alternative delivery systems 
have been proposed including liposomes, topical admin 
istration, and sustained release polymers. Work with 
diffusion of S-FU through ethylene vinyl acetate (EVA) 
and polyvinyl alcohol (PVA) membranes showed that 
EVA was impermeable to S-FU while PVA provided a 
linear release that appeared to be optimal for the sus 
tained release of 5-FU (J. Ocular Pharmacol. 
1988;10622231). Applicants found that release rates 
could be markedly decreased by heat treating the PVA 
membrane. Nonetheless, Applicants found that an im 
proved system could be made by optimizing the release 
rate using a layered EVA/PVA system. Therefore, the 
rate of release was further decreased by layering EVA 
_within the PVA to create a membrane system that was 
6X8 mm in size. 
Device Construction 
A 6 milligram pellet of S-FU was compressed under 
500 pounds of pressure into pellets measuring 2.5 mm in 
diameter. Sustained release S-FU devices were pre 
pared by'coating the 6 mg pellet of 5-FU in 300 pl of a 
10% PVA solution and allowed to dry. The pellet was 
then coated on three sides with a ?lm of prepressed 
EVA and capped by a 3 mm disc of EVA coated in 
10% PVA. The pellet was thus completely surrounded 
by EVA apart from a thin ring of PVA between the 
EVA walls and the cap. See FIG. 2. The assembly was 
then completely coated in 10% PVA and allowed to 
dry overnight. The embedded pellet was cut out in a 
disc shape using a 3.5 mm punch. A suturing strut was 
attached to the device by bonding a strip of dry 10% 
PVA to the bottom of the device with a drop of 2% 
PVA. The device was subsequently baked at 190° C for 
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three hours. With this design, Applicants were able to 
decrease the release rate to approximately 4 pg/hr 
(4.16:0.43 ug/hr, n= 3) and to sustain the release over 
one month in vitro. 
In Vivo Studies 
The above-described devices were implanted subcon 
junctivally in four rabbits to study possible in vivo tox 
icity from the device and S-FU. 
Devices containing 6 mg of S-FU were implanted on 
the exposed sclera 1.0 mm from the limbus superiorly in 
the right eye of four rabbits under general anesthesia. 
The left eye was undisturbed and used as a control. 
ERG’s and funclus photographs done prior to sacri 
?cing showed no retinal toxicity from the device or the 
5-FU. Intraocular pressure measurements showed no 
signi?cant difference between the eyes. Histology on 
the implanted eye showed no in?ammation related to 
the device or other histologic abnormality. Devices 
retrieved after sacri?cing were found to have no drug 
remaining in them. We have shown that our system for 
sustained release is biologically inert and releases S-FU 
at a rate that does not achieve toxic level. We feel this 
method of delivery has great promise in the therapy of 
the glaucoma patient at risk for failure of ?ltration sur 
gery. 
EXAMPLE 6 
Sustained Release of 5-FU Using a Heat Treated 
Membrane System of Layered Ethylene Vinylacetate 
and Polyvinyl Alcohol 
Device Construction 
A twelve milligram pellet of S-FU was compressed 
under 500 pounds of pressure into pellets measuring 2.5 
mm in diameter. Sustained release S-FU devices were 
prepared by coating the 12 mg pellet as described in 
Example 5. 
Release Rate Studies 
The devices were placed in 10 ml of isotonic buffered 
saline at 37° C. The solution was periodically sampled 
and changed to maintain sink conditions. The concen 
tration of GCV in these samples was determined by 
HPLC with UV detection at 254 nm absorbance. Ab 
sorbance values of the samples were converted to drug 
concentrations and cumulative drug release (average of 
three trials) was plotted against time. See FIG. 5. 
In Vivo Studies 
Implants prepared as described above were surgically 
implanted in the eyes of monkeys which have under 
gone ?ltering surgery. Intraocular pressure (IOP) tends 
to increase in monkeys which have undergone ?ltering 
surgery. Thus, the aim of this study was to maintain low 
IOP in monkeys after ?ltering surgery by the use of a 
sustained release 5-FU. In one eye of each monkey, a 
device containing 12 mg of S-FU was implanted under 
the conjunctiva after surgery. In the other eye of each 
monkey, a device containing no 5-FU was implanted 
under the conjunctiva after surgery. 
FIG. 6 illustrates the intraocular pressure of a mean 
average of three monkeys versus time in days. As 
clearly illustrated, the treated eyes maintained an intra 
ocular pressure below that of the untreated (control) 
eyes. 
From the foregoing description, one of ordinary skill 
in the art can easily ascertain the essential characteris 












the spirit and scope thereof, can make various changes 
and/or modifications of the invention to adapt it to 
various usages and conditions. As such, these changes 
and/or modi?cations are properly, equitably and in 
tended to be, within the full range of equivalence of the 
following claims. 
We claim: , 
1. A method for treating a mammalian organism to 
obtain a desired local or systemic physiological or phar 
macological effect comprising: 
administering a sustained release drug delivery sys 
tem to a mammalian organism in need of such treat 
ment, said drug delivery system comprising; 
(1) an inner core or reservoir comprising an effective 
amount of an agent to obtain a desired local or 
systemic physiological or pharmacological effect, 
(2) a ?rst polymer coating layer, said ?rst coating 
layer essentially impermeable to the passage of said 
agent, and said ?rst polymer coating layer covering 
at least a portion of the inner core, wherein at least 
a small portion of the inner core is not coated with 
said ?rst coating layer, and 
(3) ‘a second polymer coating layer permeable to the 
passage of said agent, wherein said second polymer 
coating layer essentially completely covers said 
?rst polymer coating layer and the uncoated por 
tion of the inner core, whereby said agent is able to 
pass through said second polymer coating layer in 
a controlled manner wherein said ?rst polymer 
coating layer and said second polymer coating 
layer are essentially insoluble and inert in body 
?uids. 
2. A method for treating a mammalian organism as 
claimed in claim 1, wherein said second coating layer 
comprises polyvinyl alcohol. 
3. A method for treating a mammalian organism as 
claimed in claim 2, wherein said ?rst coating layer com 
prises ethylene vinyl acetate. 
4. A method for treating a mammalian organism as 
claimed in claim 3, wherein said effective agent com 
prises 5-?uorouracil or ganciclovir. 
5. A method for treating a mammalian organism for 
cytomegalovirus retinitis comprising: 
administering a sustained release drug delivery sys 
tem to a mammalian organism in need of such treat 
ment, said drug delivery system comprising; 
(1) an inner core or reservoir comprising an effective 
amount of ganciclovir effective to obtain a desired 
local or systemic physiological or pharmacological 
effect, 
(2) a ?rst polymer coating layer, said ?rst polymer 
coating layer essentially impermeable to the pas 
sage of said ganciclovir, and said ?rst polymer 
coating layer covering at least a portion of the 
inner core, wherein at least a small portion of the 
inner core is not coated with said ?rst polymer 
coating layer, and 
(3) a second polymer coating layer permeable to the 
passage of said ganciclovir, wherein said second 
polymer coating layer essentially completely cov 
ers said ?rst polymer coating layer and the un 
coated portion of the inner core, whereby said 
ganciclovir is able to pass through said second 
polymer coating layer in a controlled manner. 
6. A method for treating a mammalian organism to 




placing a sustained release drug delivery system in 
contact with or within an eye of a mammalian 
organism in need of such treatment, said drug de 
livery system comprising; 
(I) an inner core having an effective amount of an 
agent to obtain a desired local or systemic physio 
logical or pharmacological effect and an inner pol 
ymer coating permeable to the passage of said 
agent covering at least a portion of said agent, 
(2) a ?rst polymer coating essentially impermeable to 
the passage of said agent, said ?rst polymer coating 
covering at least a portion but not the entire surface 
area of said inner polymer coating of said inner 
core, and 
(3) a second polymer coating permeable to the pas 
sage of said agent, wherein said second polymer 
coating essentially completely covers said ?rst 
polymer coating and any uncoated portion of the 
inner core, whereby said agent is able to pass 
through said second polymer coating, 
wherein each of the polymers selected to make the 
device are essentially insoluble and inert in body 
?uids and compatible with eye tissues, and 
allowing said agent to pass through said second poly 
mer coating to obtain a desired effect. 
7. The method for treating a mammalian organism 
according to claim 6, wherein said inner coating of said 
inner core comprises polyvinyl alcohol. 
8. The method for treating a mammalian organism 
according to claim 6, wherein said ?rst coating com 
prises ethylene vinyl acetate. 
9. The method for treating a mammalian organism 
according to claim 6, wherein said second coating com 
prises polyvinyl alcohol. 
10. The method for treating a mammalian organism 
according to claim 6, wherein said agent is ganciclovir 
or 5~?uorouracil. 
11. The method for treating a mammalian organism 
according to claim 6, wherein said inner coating of said 
inner core comprises polyvinyl alcohol, said ?rst coat 
ing comprises ethylene vinyl acetate, said second coat 
ing comprises polyvinyl alcohol and said agent is cy 
closporin, dexamethasone, 5-?uorouracil or ganci 
clovir. 
12. A sustained release drug delivery system suitable 
for placing in contact with or within the eye to provide 
a desired physiological or pharmacological effect com 
prising: 
(1) an inner core having an effective amount of an 
agent to obtain a desired local or systemic physio 
logical or pharmacological effect and an inner pol 
ymer coating permeable to the passage of said 
agent covering at least a portion of said agent, 
(2) a ?rst polymer coating essentially impermeable to 
the passage of said agent, said ?rst polymer coating 
covering at least a portion but not the entire surface 
area of said inner polymer coating of said inner 
core, and 
(3) a second polymer coating permeable to the pas 
sage of said agent, wherein said second polymer 
coating essentially completely covers said ?rst 
polymer coating and any uncoated portion of the 
inner core, 
wherein each. of the polymers selected to make the 
device are essentially insoluble and inert in body 
?uids and compatible with eye tissues. 
13. The sustained release drug delivery system suit 












wherein said inner coating of said inner core comprises 
polyvinyl alcohol. 
14. The sustained release drug delivery system suit 
able for placing in the eye according to claim 12, 
wherein said ?rst coating comprises ethylene vinyl 
acetate. 
15. The sustained release drug delivery system suit 
able for placing in the eye according to claim 12, 
wherein said second coating comprises polyvinyl alco 
hol. 
16. A method for providing controlled and sustained 
administration of an agent effective in obtaining a de 
sired local or systemic physiological or pharmacologi 
cal‘ effect comprising: 
surgically implanting a sustained release drug deliv 
ery system at a desired location, said drug delivery 
system comprising; 
(1) an inner core or reservoir comprising an effective 
amount of an agent effective in‘obtaining a desired 
physiological or pharmacological effect, 
(2) a polymer coating layer which is essentially im 
permeable to the passage of said effective pgent, 
said impermeable layer covering at least a portion 
or the inner core, wherein at least a small portion of 
the inner core is not coated with said impermeable 
polymer coating layer, and 
(3) a polymer coating layer which essentially com 
pletely covers the inner core and is permeable to 
the passage of said effective agent whereby said 
agent is able to pass through said polymer coating 
layer in a controlled manner. 
17. A method as claimed in claim 16, wherein said 
device is surgically implanted within the vitreous of the 
eye. 
18. The sustained release drug delivery system suit 
able for placing in the eye according to claim 12, 
wherein said agent is cyclosporin, dexamethasone, 5 
?uorouracil or ganciclovir. 
19. A method as claimed in claim 17, wherein said 
permeable coating layer comprises polyvinyl alcohol. 
20. A method as claimed in claim 18, wherein said 
impermeable coating layer comprises ethylene vinyl 
acetate. 
21. A method as claimed in claim 20, wherein said 
effective agent is ganciclovir or 5-?uorouracil. 
22. A sustained release drug delivery system compris 
mg: 
(A) an inner core or reservoir comprising an effective 
amount of an agent effective in obtaining a desired 
local or systemic physiological or pharmacological 
effect, 
(B) a ?rst polymer coating layer, said ?rst polymer 
coating layer impermeable to the passage of said 
effective agent, and said ?rst polymer coating layer 
covering at least a portion of the inner core, 
wherein at least a small portion of the inner core is 
not coated with said ?rst polymer coating layer, 
and 
(C) a second polymer coating layer, said second poly 
mer coating layer permeable to the passage of said 
effective agent, wherein said second polymer coat 
ing layer essentially completely covers the ?rst 
polymer coating layer and the uncovered portion 
of the inner core, said ?rst polymer coating layer 
and said second polymer coating layer being essen 
tially insoluble and inert in body ?uids. 
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23. A sustained release drug delivery system as 
claimed in claim 22, wherein said second coating layer 
comprises polyvinyl alcohol. 
24. A sustained release drug delivery system as 
claimed in claim 23, wherein said ?rst coating layer 
comprises ethylene vinyl acetate. 
25. A sustained release drug delivery system as 
claimed in claim 24, wherein said effective agent is 
ganciclovir or 5-fluorouracil. 
26. The method for treating a mammalian organism as 
claimed in claim 1, wherein said drug delivery system is 
attached to an intraocular lens or the haptic extending 
from said intraocular lens. 
27. The sustained release drug delivery system suit 
able for placing in the eye according to claim 12, 
wherein said inner coating of said inner core comprises 
polyvinyl alcohol, said ?rst coating comprises ethylene 
vinyl acetate, said second coating comprises polyvinyl 
alcohol and said agent is ganciclovir or 5-?uorouracil. 
28. The sustained release drug delivery system ac 
cording to claim 22, further comprising a polymeric 
layer between said inner core or reservoir and said 
impermeable coating, whereby said agent is able to pass 
through said polymeric layer 
29. A sustained release drug delivery system compris 
mg: 
(a) in inner core or reservoir comprising an effective 
amount of an agent effective in obtaining a desired 
local or systemic physiological or pharmacological 
effect, 
(b) a ?rst polymer coating layer, said ?rst polymer 
coating layer impermeable to the passage of said 
effective agent, and said ?rst polymer coating layer 
covering at least a portion of the inner core, 
wherein at least a small portion of the inner core is 










(c) a second polymer coating layer, said second poly 
mer coating layer permeable to the passage of said 
effective agent, wherein said second polymer coat 
ing layer essentially completely covers the ?rst 
polymer coating layer and the uncovered portion 
of the inner core, wherein said sustained drug de 
livery system is attached to an intraocular lens or 
the haptic extending from said intraocular lens. 
30. The sustained drug release delivery system as 
claimed in claim 29, wherein said effective agent is 
ganciclovir, 5-?uorouracil, colchicine or dexametha 
sone. 
31. The method for treating a mammalian organism 
according to claim 1, wherein said sustained release 
drug delivery system is placed in contact with or within 
an eye of said mammalian organism. 
32. The method for treating a mammalian organism 
according to claim 1, wherein said sustained release 
drug delivery system further comprises a polymeric 
layer between said inner core or reservoir and said 
impermeable coating, whereby said agent is able to pass 
through said polymeric layer between said inner core or 
reservoir and said impermeable coating. 
33. The method for treating a mammalian organism 
according to claim 22, wherein said core consists essen 
tially of said agent or a pharmaceutically acceptable salt 
of said agent. 
34. The method for treating a mammalian organism 
according to claim 1, wherein said core consists essen 
tially of said agent or a pharmaceutically acceptable salt 
of said agent. 
35. The sustained release drug delivery system ac 
cording to claim 22, wherein said polymers used to 
fabricate said ?rst and second layer are compatible with 
eye tissues. between said inner core or reservoir and 
said impermeable coating. 
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